Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Blood

Volumn 117, Issue 21, 2011, Pages 5600-5606

  Cortes, Jorge E ^a   Hochhaus, Andreas ^b   Le Coutre, Philipp D ^c   Rosti, Gianantonio ^d   Pinilla Ibarz, Javier ^e   Jabbour, Elias ^a   Gillis, Kathryn ^f   Woodman, Richard C ^f   Blakesley, Rick E ^f   Giles, Francis J ^g   Kantarjian, Hagop M ^a   Baccarani, Michele ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b Universit tsklinikum Jena   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONJUNCTIVITIS; CONSTIPATION; CROSS TOLERANCE; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

EID: 79957616017     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-318949     Document Type: Article

References (20)

1. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084-1086. (Pubitemid 32267980)
2. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26(17):2911-2915.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330- 1340. (Pubitemid 29196596)
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
5. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.
6. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD.AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765-1769. (Pubitemid 43882564)
7. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540- 3546. (Pubitemid 350159618)
8. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834-1839. (Pubitemid 351451490)
9. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2010;362(24):2251-2259.
10. Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87(2):197-203.
11. The National Cancer Institute. Common Terminology Criteria for Adverse Events Version 3.0. http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed April 14, 2011.
12. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141-1145.
13. Hochhaus AH, Giles F, Apperley J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study [abstract]. Haematologica. 2009; 94(suppl 2):256. Abstract 631.
14. Moreno E, Macias E, Davila I, Laffond E, Ruiz A, Lorente F. Hypersensitivity reactions to cephalosporins. Expert Opin Drug Saf. 2008;7(3):295-304. (Pubitemid 351802829)
15. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(12):1116-1128. (Pubitemid 350182968)
16. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49(4):615-619. (Pubitemid 351517198)
17. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247-274.
18. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004;15(4):275-286. (Pubitemid 38781051)
19. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929-2934. (Pubitemid 32691937)
20. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100(1):116-121. (Pubitemid 37553546)